WO2009086126A3 - Natriuretic polypeptides - Google Patents

Natriuretic polypeptides Download PDF

Info

Publication number
WO2009086126A3
WO2009086126A3 PCT/US2008/087714 US2008087714W WO2009086126A3 WO 2009086126 A3 WO2009086126 A3 WO 2009086126A3 US 2008087714 W US2008087714 W US 2008087714W WO 2009086126 A3 WO2009086126 A3 WO 2009086126A3
Authority
WO
WIPO (PCT)
Prior art keywords
natriuretic
polypeptides
document
natriuretic polypeptides
activities
Prior art date
Application number
PCT/US2008/087714
Other languages
French (fr)
Other versions
WO2009086126A2 (en
Inventor
John C. Burnett, Jr.
Candace Y.W. Lee
Original Assignee
Mayo Foundation For Medical Education And Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation For Medical Education And Research filed Critical Mayo Foundation For Medical Education And Research
Publication of WO2009086126A2 publication Critical patent/WO2009086126A2/en
Publication of WO2009086126A3 publication Critical patent/WO2009086126A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Abstract

This document provides natriuretic polypeptides. For example, this document provides polypeptides having a natriuretic activity. In some cases, a polypeptide provided herein can have natriuretic activities without lowering blood pressure. This document also provides methods and materials for inducing natriuretic activities within a mammal.
PCT/US2008/087714 2007-12-21 2008-12-19 Natriuretic polypeptides WO2009086126A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1590307P 2007-12-21 2007-12-21
US61/015,903 2007-12-21

Publications (2)

Publication Number Publication Date
WO2009086126A2 WO2009086126A2 (en) 2009-07-09
WO2009086126A3 true WO2009086126A3 (en) 2009-09-17

Family

ID=40825039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/087714 WO2009086126A2 (en) 2007-12-21 2008-12-19 Natriuretic polypeptides

Country Status (1)

Country Link
WO (1) WO2009086126A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2348114T3 (en) 2004-04-21 2018-09-03 Alexion Pharma Inc BONE DELIVERY CONJUGATES AND PROCEDURE TO USE IT FOR TARGETING PROTEINS AGAINST BONE
ES2554713T3 (en) 2005-04-07 2015-12-22 Cardiorentis Ag Use of a natriuretic peptide to treat heart failure
US20120108514A1 (en) 2009-07-09 2012-05-03 University Of Iowa Research Foundation Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
WO2012013597A1 (en) * 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Substances and the use thereof for influencing natriuretic peptide receptors
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
CN103906761B (en) 2011-08-30 2016-12-21 梅约医学教育与研究基金会 Profit sodium polypeptide
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US20140213519A1 (en) * 2013-01-25 2014-07-31 Cardiorentis Ltd. Methods of treating cardiovascular indications
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
WO2016090251A1 (en) 2014-12-05 2016-06-09 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
RU2745528C2 (en) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Production of alkaline phosphatases
US11229686B2 (en) 2015-09-28 2022-01-25 Alexion Pharmaceuticals, Inc. Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
CA3019726A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
JP7018933B2 (en) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド How to treat bronchomalacia
AU2018243320A1 (en) 2017-03-31 2019-10-10 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (HPP) in adults and adolescents
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434133A (en) * 1991-01-31 1995-07-18 Suntory Limited CNP analog peptides and their use
US6818619B2 (en) * 1999-12-17 2004-11-16 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
US6828107B2 (en) * 1997-09-11 2004-12-07 Shionogi & Co., Ltd. Immunoassay method for BNP
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434133A (en) * 1991-01-31 1995-07-18 Suntory Limited CNP analog peptides and their use
US6828107B2 (en) * 1997-09-11 2004-12-07 Shionogi & Co., Ltd. Immunoassay method for BNP
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6818619B2 (en) * 1999-12-17 2004-11-16 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides

Also Published As

Publication number Publication date
WO2009086126A2 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
WO2009086126A3 (en) Natriuretic polypeptides
WO2010048308A3 (en) Natriuretic polypeptides
WO2008031045A3 (en) Aquaretic and natriuretic polypeptides lacking vasodilatory activity
EP2765139A3 (en) Natriuretic polypeptides
WO2010002583A3 (en) Natriuretic polypeptides with unique pharmacologic profiles
IL196931A (en) Diuretic and natriuretic polypeptides lacking the blood pressure lowering property and uses thereof
WO2007035600A3 (en) Natriuretic activities
WO2006105338A3 (en) Fc VARIANTS WITH OPTIMIZED PROPERTIES
EP1951166B8 (en) Transapical heart valve delivery system
AU2006272804A8 (en) Concentrated protein lyophilates, methods, and uses
WO2007073484A3 (en) Methods and systems for conducting research operations
EP1865888A4 (en) Devices, systems, and methods for reshaping a heart valve annulus
WO2005074546A3 (en) Modified human growth hormone polypeptides and their uses
WO2006069220A3 (en) Modified human growth hormone
EP2214700A4 (en) Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses
WO2009024859A3 (en) Stent-valves for valve replacement and associated methods and systems for surgery
PL1824876T3 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
EP1910550A4 (en) Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis
PL1781682T3 (en) B7-h5, a costimulatory polypeptide
EP1733749A4 (en) Syringe with connector, connector for syringe, and syringe
EP2360173A4 (en) Cytotoxic t cell epitope peptide for sars coronavirus, and use thereof
WO2008098936A3 (en) Valve assembly
IL185657A (en) Human skin equivalents expressing exogenous polypeptides, method for their preparation and uses thereof
IL207648A0 (en) Polypeptide having glyoxalase iii activity, polynucleotied encoding the same and uses thereof
WO2008008917A3 (en) Hydroxyapatite particles

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08868068

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08868068

Country of ref document: EP

Kind code of ref document: A2